AngioDynamics, Inc. v. Biolitec AG

991 F. Supp. 2d 299, 2014 WL 1046873, 2014 U.S. Dist. LEXIS 35176
District Court, D. Massachusetts·Decided March 18, 2014·No. C.A. No. 09-cv-30181-MAP·Published·Cited by 4 cases

Opinion

MEMORANDUM AND ORDER REGARDING DAMAGES

PONSOR, District Judge.

I. INTRODUCTION

On January 14, 2014, this court entered default judgment against Defendants on the issue of liability. AngioDynamics, Inc. v. Biolitec AG, 991 F.Supp.2d 283, 2014 WL 129035 (D.Mass. Jan. 14, 2014). Counsel then appeared for argument on February 24, 2014, to set forth their positions on the question of damages. Because the allegations in the complaint are accepted as true, Plaintiff is entitled to recover actual damages, trebled under Mass. Gen. Laws chapter 93A; pre-judgment interest; and reasonable attorney’s fees and costs. The court will therefore enter judgment for Plaintiff in the amount of $74,920,422.57.

II. BACKGROUND

The background of this litigation has been exhaustively detailed on a number of occasions. See AngioDynamics, Inc. v. Biolitec AG, 910 F.Supp.2d 346 (D.Mass.2012), aff'd, 711 F.3d 248 (1st Cir.2013); AngioDynamics, Inc. v. Biolitec, Inc., 2011 WL 3157312 at *1-2 (D.Mass. July 25, 2011). The facts relevant to the issue of damages are as follows.

On September 20, 2012, the Northern District of New York found Defendant Biolitec, Inc. (“BI”) liable to Plaintiff in the amount of $16,463,846.94, plus pre-judgment interest, for failing to indemnify Plaintiff as required under the parties’ Supply and Distribution Agreement (“SDA”). Angiodynamics, Inc. v. Biolitec, Inc., No. 1:08-cv-0004, Mem. & Order (N.D.N.Y. Sept. 27, 2011). This damage award was based on amounts Plaintiff had previously been required to pay to settle litigation brought against it by two entities — VNUS and Diomed — that BI, in violation of the SDA, had failed to hold Plaintiff harmless against. One year later, that court entered partial, final judgment for Plaintiff in the amount of $23,156,287.00. Angiodynamics, Inc. v. Biolitec, Inc., No. 1:08-cv-0004, Partial J. (N.D.N.Y. Nov. 8, 2012). BI subsequently appealed the decision to the Second Circuit Court of Appeals.

In January 2013, with that judgment still outstanding, BI filed for bankruptcy in the U.S. Bankruptcy Court for the District of New Jersey. (Chp. 11 Pet., Dkt. No. [302]*302400, Ex. 3.) On April 3, 2013, the bankruptcy court appointed a trustee, pursuant to 11 U.S.C. § 1104, and removed control of the company from Defendant Neuberger.

The trustee, on behalf of BI, entered into a settlement agreement with Plaintiff on July 16, 2013. (Settlement Agreement, Dkt. No. 400, Ex. 7.) As part of that settlement, Plaintiff agreed to forego efforts to seek monetary damages against BI in the New York litigation — BI apparently had few assets at any rate — with the understanding that Plaintiff would instead pursue its remedies against BI and the other Defendants in this forum. In return, BI agreed to withdraw its appeal before the Second Circuit. (Id.) On August 9, 2012, the Bankruptcy Court approved the settlement. (Bankr.Ct.Approval, Dkt. No. 400, Ex. 8.) Two weeks later the Second Circuit dismissed BI’s appeal. (Ct.App.Mandate, Dkt. No. 400, Ex. 2.) At that point, the New York judgment became final.

In the litigation before this court, Plaintiff has attempted to recover the New York judgment from Defendants. Plaintiff accused Defendants Biolitec AG (“BAG”), Biomed Technology Holdings, Ltd. (“Biomed”), and Wolfgang Neuberger — all entities closely associated with BI — of (among other things) wrongfully diverting assets from BI in an effort to render BI judgment-proof and escape paying the New York judgment. The specific claims asserted by Plaintiff in this case include tortious interference with a contract, fraudulent transfer, and violation of Mass. Gen. Laws chapter 93A. Plaintiff contends that the close relationship among the parties and their course of conduct permits it to reach through the corporate structure and, as the phrase goes, “pierce the corporate veil.”

After nearly five years of litigation characterized by increasingly recalcitrant behavior on Defendants’ part, the court allowed two of Plaintiffs Motions for Default Judgment stemming from Defendants’ bad-faith behavior during pre-trial discovery. AngioDynamics, Inc. v. Biolitec AG, 991 F.Supp.2d 283, 2014 WL 129035 (D.Mass. Jan. 14, 2014). After entering judgment on the issue of liability for Plaintiff, the court heard argument on damages on February 24, 2014. Following this, the court provided additional time for Defendants to file a sur-reply, (Dkt. No. 416), and took the matter under advisement.

III. DISCUSSION

Since the court entered default judgment against Defendants on the issue of liability, it is obliged to accept the allegations in the complaint as true. McKinnon v. Kwong Wah Rest., 83 F.3d 498, 506 n. 5 (1st Cir.1996); see also Ortiz-Gonzalez v. Fonovisa, 277 F.3d 59, 62-63 (1st Cir.2002). Plaintiff contends that, given this, the damage calculation in the case is straightforward: Defendants owe the $23 million in damages awarded in the Northern District of New York, trebled under chapter 93A, along with pre-judgment interest, attorney’s fees, and costs.

Defendants, citing principles of res judicata, argue that they cannot be “bound” by the New York judgment.1 In addition, they reprise several arguments the court has already rejected, attempting to demonstrate substantively that Plaintiff has failed to assert any valid cause of action. [303]*303The facial substantive deficiencies in the complaint, Defendants say, make it improper to award Plaintiff any remedy, even though the court has defaulted them due to their pretrial misconduct. Analysis of Defendants’ arguments quickly reveals their flaws.

A. “Res Judicata” Defense

Defendants broadly assert that the New York judgment cannot provide the basis for an award of damages because they did not have a full and fair opportunity to litigate that case through appeal. Implicitly tied up in this argument is the assumption that Plaintiff seeks through this litigation to enforce the New York judgment; Plaintiff, they say, is essentially invoking the doctrine of res judicata to preclude them from defending themselves. In their view, the parties must now re-litigate the issue of whether the Supply and Distribution Agreement obligated BI to defend and indemnify Plaintiff and whether BI breached that contract. Defendants concede that these issues were the subject of the extensive litigation in the Northern District of New York, but they take the position that, because BI’s trustee in bankruptcy settled the appeal of the New York judgment to the Second Circuit over their protest, this court is now barred from using the judgment in calculating damages.

This argument has no merit.

Free access — add to your briefcase to read the full text and ask questions with AI

AngioDynamics, Inc. v. Biolitec AG, 991 F. Supp. 2d 299, 2014 WL 1046873, 2014 U.S. Dist. LEXIS 35176 (D. Mass. 2014).

991 F. Supp. 2d 299 (AngioDynamics, Inc. v. Biolitec AG) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

AngioDynamics, Inc. v. Biolitec AG
305 F. Supp. 3d 300 (District of Columbia, 2018)
AngioDynamics, Inc. v. Biolitec AG
780 F.3d 429 (First Circuit, 2015)
In re Biolitec, Inc.
528 B.R. 261 (D. New Jersey, 2014)